Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 4/20 | 0.45 |
| ▸ | FPR2 | P25090 | 4/20 | 0.45 |
| ▸ | GRPR | P30550 | 4/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402423 | 0.89 | REN (0.60) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL27624718 | 0.89 | REN (0.51) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL16350346 | 0.88 | REN (0.49) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL12972224 | 0.88 | REN (0.49) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL27624690 | 0.87 | SLC15A2 (0.57) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL12374166 | 0.87 | REN (0.54) | RENERAP2ERAP1LNPEPGRPR | |
| SCHEMBL24064977 | 0.84 | GRPR (0.59) | GRPR | |
| SCHEMBL16317506 | 0.83 | REN (0.51) | RENGRPR | |
| SCHEMBL27644992 | 0.82 | GRPR (0.53) | RENGRPR | |
| SCHEMBL23734106 | 0.81 | REN (0.46) | RENERAP2ERAP1LNPEPSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250133-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | GRPR, GIPR, GHRHR | REN 994/4885ERAP2 876/4885ERAP1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.